Background. Organic nitrates such as nitroglycerin and isosorbide dinitrate are useful in the treatment of congestive heart failure (CHF), but tolerance develops rapidly during continuous administration. Because combination therapy of nitrate and hydralazine has been shown to provide both short-and long-term benefit but nitrate alone produces hemodynamic tolerance, we questioned whether hydralazine can preserve the favorable preload effects of nitroglycerin.
O rganic nitrates, such as nitroglycerin and isosorbide dinitrate, are a class of vasodilators useful for the treatment of congestive heart failure (CHF) because of their beneficial reduction of preload and relief of venous and pulmonary congestion often associated with this disease. However, organic nitrate tolerance has been observed as soon as 12 hours during continuous administration (intravenous or transdermal) to patients with heart failure. Intermittent nitrate dosing has been proposed as a method of avoiding nitrate tolerance,1 but this approach is problematic in nitrate monotherapy because the patient is left unprotected during the "dose-oW' period. Therefore, the continuous maintenance of the beneficial hemodynamic effects of nitrates without development of pharmacological tolerance remains a challenge.
Interestingly, another nitrovasodilator, that is, sodium nitroprusside, has also been found useful in the treatment of acute heart failure, but pharmacological tolerance to this compound is not evident.2 This favorable characteristic has been attributed to the more significant afterload effect of nitroprusside compared with nitroglycerin.2 A treatment hemodynamically equal to intravenous sodium nitroprusside is the combination of hydralazine and a nitrate, which has been shown to provide beneficial effects after short-term3 as well as long-term4 therapy in patients with CHF. The reason for this long-term benefit of the hydralazine/nitrate combination has not been determined. Because the hydralazine/nitrate combination provides sustained benefit but nitrate alone produces hemodynamic tolerance, it is logical to question whether hydralazine can preserve the favorable preload effects of an organic nitrate. So far, no reported study has addressed this clinically important question. Therefore, in the present study, we examined the effect of hydralazine coadministration on the ventricular hemodynamics of intravenous nitroglycerin in a rat model of CHF. We have previously shown5 that this animal model can mimic the hemodynamic and temporal behavior of nitroglycerin-induced tolerance in left ventricular end-diastolic pressure (LVEDP) seen in patients. Our 20 minutes, and no spectroscopic evidence of hydralazine degradation was observed. After 1-hour equilibration, the mounted ring segments were precontracted with phenylephrine (0.5 1£M), and cumulative nitroglycerin concentration/ response curves were determined. Ring segments isolated from the same animal were paired for testing in at least two of the three preincubation treatments.
Log molar EC50 and Em., values were obtained for each individual run by fitting the four-parameter logistic function to the concentration/relaxation data using PCNONLIN. This methodology has been used previously in our laboratory for the examination of vascular tolerance toward nitrates.8
Results
When hydralazine alone was administered as two 0.1-mg bolus doses 30 minutes apart, a significant reduction in LVPSP was observed in this rat model of CHF ( Figure 1 ). The magnitude of LVPSP changes (12±3% maximal reduction) were comparable to those seen during SNAP infusion (15+3% reduction).7 Using this dosing strategy of hydralazine alone, LVPSP remained depressed for approximately 4 hours, whereas LVEDP remained unchanged throughout. Heart rate increased slightly during hydralazine administration, although the difference from baseline was not statistically significant.
Infusion of nitroglycerin in CHF rats produced prompt initial reductions in LVEDP of 46±3% but no significant changes in LVPSP ( Figure 2 ). These ventricular hemodynamic effects are consistent with the predominantly venous action of this drug. When nitroglycerin infusion was continued, these initial hemodynamic effects were not maintained, and LVEDP returned to near-baseline values within 6 hours, indicating tolerance development. We have previously shown that this rat model of CHF behaves similarly to CHF patients with respect to nitroglycerin effects and tolerance properties5 and that this apparent tolerance is not a result of any changes in the availability of the drug during infusion.7 Figure 2 also shows the effects of hydralazine and nitroglycerin coadministration on left ventricular pressures. The hydralazine doses (2x0.1-mg bolus injections) were administered at 1.5 and 2.0 hours during nitroglycerin infusion. LVPSP was not significantly different from baseline during nitroglycerin infusion before hydralazine administration, but it promptly decreased after the first bolus dose and remained depressed throughout the 10-hour nitroglycerin infusion period. Importantly, LVEDP tolerance to nitroglycerin infusion alone, as demonstrated in Figure 2 Experiments were then carried out to examine whether hydralazine could reduce nitroglycerin-induced vascular tolerance observed in vitro (Figure 3) Discussion Although nitrate tolerance is a well-recognized clinical problem, the underlying mechanism of tolerance development has not been fully defined. In vitro studies have shown that incubation of vascular segments with high concentrations of nitroglycerin causes a reduced relaxation response.10 Based on a number of in vitro studies, Needleman and Johnson,11 in their classic "sulfhydryl depletion" hypothesis, first proposed that nitrate tolerance is a result of depletion of critical intracellular sulfhydryl pools, leading to a loss of vasodilatory response. However, conflicting data exist that argue against the validity of this hypothesis.'2 Reduction in the vascular metabolic activation of nitrates12 and/or diminished guanylate cyclase activation13 have also been proposed as mechanisms of specific vascular tolerance. Based on the literature, these hypotheses of nitrate tolerance, based primarily on in vitro data, have gained wide acceptance. However, the concentrations used to produce in vitro vascular tolerance vastly exceed the typical plasma concentrations of nitrates observed in patients with heart failure. In addition, these in vitro findings were obtained in the absence of systemic regulatory mechanisms, which could play an important role in modulating vascular activity. Thus, the applicability of these in vitro mechanisms of nitrate tolerance to the in vivo situation can be questioned.
Another possible hypothesis for the mechanism of nitrate tolerance suggests that chronic nitrate administration evokes the activation of compensatory processes responsible for regulating systemic hemodynamics,14 involving, for example, the sympathetic nervous system and/or the renin-angiotensin-aldosterone axis. Studies in CHF patients have shown that various neurohormonal changes can occur during long-term nitrate therapy. Elevations in plasma renin activity, decreases in hematocrit, and increases in body weight have all been observed during continuous long-term nitroglycerin therapy,' suggesting that nitrate tolerance in vivo may result, at least in part, from systemic compensatory changes.
The successful development of an animal model to study in vivo nitrate tolerance in heart failure affords an opportunity to examine tolerance mechanisms without clinical restrictions and complications. Such complications include those incurred by the coadministration of diuretics and digitalis preparations, which can confound data interpretation, and difficulties encountered in performing invasive hemodynamic monitoring for extended durations. An animal model also provides the opportunity to conduct in vitro studies with isolated blood vessels in parallel. In this article, we show that nitrate tolerance in left ventricular hemodynamics can be induced by an infusion regimen of 10 ,Lg/min (or approximately 18 btg/kg/min) of nitroglycerin. Although this dose is extrapolated to be approximately 1.3 mg/min for a 70-kg person, the hemodynamic effects produced in this animal model (i.e., about 40-50% reduction in LVEDP without substantial change in heart rate) are similar to those seen with nitroglycerin therapy in CHF patients. 3 The difference in the doses used is probably a result of interspecies differences in hemodynamic sensitivity toward nitrates.
Intravenous administration of hydralazine alone to CHF rats produced significant reductions in LVPSP and no change in LVEDP. These results are consistent with investigations in heart failure patients15 and in an identical rat model of heart failure, 16 showing that hydralazine causes reductions in blood pressure and increases in cardiac output with little or no effect on the venous circulation. Although hydralazine is commonly administered to CHF patients orally, we chose to use intravenous administration, thus allowing the titration to a predetermined effect. The effects of oral hydralazine administration in our animal preparation have not been determined.
We have shown earlier7 that SNAP, an S-nitrosothiol nitrovasodilator that produced significant effects on LVPSP and LVEDP, did not exhibit tolerance in LVEDP in CHF rats after 10 hours of continuous infusion. Consistent with this finding, the hydralazine/ nitroglycerin combination, which produced both afterload and preload effects, also appeared to avoid the development of nitrate tolerance in vivo. The results of these studies may suggest that balanced arterial and venous actions of a vasodilator, or a vasodilator combination, could be an important determinant of both subchronic and long-term efficacy. This view is supported by clinical evidence that the combination treatment of hydralazine plus isosorbide dinitrate4 or enalapril alone17 can provide long-term improvements in mortality and morbidity in CHF patients. We have not performed any experiments examining the effects of repeated dosing or more prolonged infusions in this animal preparation to determine the duration of this favorable hydralazine/nitroglycerin drug interaction.
Our data confirmed previous findings'8 that nitrate tolerance is probably not a result of changes in drug pharmacokinetics. Administration of hydralazine did not alter steady-state nitroglycerin concentrations, and the values observed here are similar to those observed when nitroglycerin was infused alone.7 Plasma concentrations of dinitrate metabolites were also similar to those resulting when nitroglycerin was infused alone7 (data not shown).
Our results also suggest that the beneficial effects of hydralazine on nitroglycerin-induced tolerance were not a result of localized vascular interaction between the two drugs. Preincubation of hydralazine with nitroglycerin, at a hydralazine concentration that mimicked the in vivo situation, did not counteract the toleranceinducing effect of nitroglycerin in vitro. The fact that hydralazine prevented nitroglycerin tolerance in vivo but not in vitro suggests that hemodynamic nitrate tolerance may be better related to systemic neurohormonal compensatory changes than to vascular biochemical alterations. The lack of a localized interaction between hydralazine and nitroglycerin may not be surprising because these two vasodilators operate through two apparently independent biochemical path- 
